Welcome to Medications.com

BioSante's Gamble Against Generics - Motley Fool

The drug could become a low-margin sub-$100 million treatment, like Novartis' (NYSE: NVS) and Noven Pharmaceuticals' (Nasdaq: NOVN) Vivelle-dot, ...

http://www.fool.com/investing/hig... | Posted: Tue Jan 29 13:49:38 -0500 2008




© 2002-2007, Skylabs Inc.  |  About Us  |  Disclaimer/Terms of Use  |  Advertise  |  Contact Us  |  Site Map  |  Developed by: W3matter.com | Sleep Apnea